Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Anthracycline may reduce risk of heart problems

  • Comment
Giving a chemotherapy infusion over six or more hours may reduce the risk of heart problems from commonly used cancer drugs, according to a review of research.

Giving a chemotherapy infusion over six or more hours may reduce the risk of heart problems from commonly used cancer drugs, according to a review of research.

Anthracycline drugs, which include doxorubicin, are used to treat a wide range of cancers such as leukaemia, lymphoma, lung and breast cancer. The drugs carry a risk of causing damage to the heart leading to heart failure.

Dutch researchers found that the rate of heart failure was significantly lower in patients who had an anthracycline infusion which lasted six hours compared with patients who had shorter infusion times.

The review of five studies of 557 patients found that the longer infusions cut the risk of heart failure by almost 75%. The treatment effect on the patients' tumour was the same, regardless of the infusion time.

This group of drugs is commonly used in children and the researchers call for the effect of longer infusions to be evaluated in children.

Cochrane Database of Systematic Reviews (2006) Online publication. DOI: 10.1002/14651858.CD005008.pub2.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs